BK1188 Post-pandemic Stocks
- 393.347
- +1.872+0.48%
CSPC Group (01093.HK) cancelled 26.628 million shares on May 3
Gelonghui, May 3, 丨 Shiyao Group (01093.HK) announced that on May 3, 2024, 26.628 million shares have been cancelled.
DBS: Lowering the target price of BYD Electronics (00285.HK) to HK$34, the automotive electronics business is on an upward trend
According to a research report released by DBS, the target price of BYD Electronics (00285.HK) was reduced from HK$38 to HK$34, which is equivalent to 14 times the predicted price-earnings ratio. This is the historical average. The profit forecast for this year and next two years was lowered by 9% and 3% to reflect the pressure on gross profit due to increased smartphone contributions.
Express News | Hong Kong's Hang Seng Index closed up 2.5%, while the Hang Seng Technology Index closed up 4.45%. Shangtang closed up about 36%, NIO Auto closed up about 21%, Country Garden Service closed up about 13%, and Ali Health rose 11%.
Sihuan Pharmaceutical Unit's Lung Cancer Drug NDA Accepted by NMPA, Stocks Shoot Over 10%
Sihuan Pharmaceutical Holdings Group (HKG:0460) said its New Drug Application (NDA) to China's National Medical Products Administration (NMPA) was accepted for the lung cancer drug Dexitinib tablets,
Hong Kong stocks started “booming” in May! The Hang Seng Index reclaimed the 18,000 mark, and in April, Demon Stock added another 30% assist
On May 2, Hong Kong stocks ushered in the first trading day of May, and the three major stock indexes continued their major counterattack!
Most of the Hong Kong Apple concept stocks rose higher. Qiu Titanium Technology rose more than 10%, Shunyu Optical Technology rose more than 4%, and BYD Electronics rose more than 1%.
Most of the Hong Kong Apple concept stocks rose higher. Qiu Titanium Technology rose more than 10%, Shunyu Optical Technology rose more than 4%, and BYD Electronics rose more than 1%.
Changes in Hong Kong stocks | Cornerstone Pharmaceutical-B (02616) rose more than 26%, leading the innovative drug concept, ASCO catalyzes market conditions, institutions are optimistic about policy+health insurance marginal improvement
Zhitong Finance App learned that innovative drug concept stocks showed strong performance. As of press release, Cornerstone Pharmaceutical-B (02616) rose 26.14% to HK$1.11; Cansino Biotech (06185) rose 16.91% to HK$20.95; Gacos-B (01167) rose 14.2% to HK$1.93; Nuocheng Jianhua (09969) rose 12.31% to HK$5.2; Rongchang Biotech (09995) rose 10.2% to HK$30.8. According to the news, the research title of the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting was on April 25
Changes in Hong Kong stocks 丨 Biotech stocks continue to strengthen, the cornerstone pharmaceutical industry rises nearly 23%
Glonghui, May 2 | Cornerstone Pharmaceuticals rose nearly 23%, Cansino Biotech rose nearly 14%, Lepu Biotech rose more than 10%, and Pharmaceutical Kangde rose nearly 8.5%.
Hong Kong Internet healthcare stocks continued to rise in the afternoon. Ali Health rose more than 9%, Jingdong Health rose nearly **** An Good Doctor rose nearly 8%, and Zhongan Online and Jingdang Health both rose more than 4%.
Hong Kong Internet healthcare stocks continued to rise in the afternoon. Ali Health rose more than 9%, Jingdong Health rose nearly **** An Good Doctor rose nearly 8%, and Zhongan Online and Jingdang Health both rose more than 4%.
Hong Kong biotechnology stocks continued to strengthen. Cornerstone Pharmaceuticals rose nearly 23%, Gacos rose more than 14%, Cansino Biotech rose nearly 14%, Lepu Biotech rose more than 10%, and Pharmacom Kangde rose nearly 8.5%.
Hong Kong biotechnology stocks continued to strengthen. Cornerstone Pharmaceuticals rose nearly 23%, Gacos rose more than 14%, Cansino Biotech rose nearly 14%, Lepu Biotech rose more than 10%, and Pharmacom Kangde rose nearly 8.5%.
Sihuan Pharmaceutical (00460.HK): Xuanzhu Biotech independently developed a Class 1 innovative drug “daxitinib tablets” and applied for marketing to the State Drug Administration and accepted
On May 2, Ge Longhui Pharmaceutical (00460.HK) announced that the Class 1 innovative anti-tumor drug “daxitinib tablets” (product code: XZP-3621) independently developed by Xuanzhu Biotechnology Co., Ltd. (“Xuanzhu Biology”), a non-wholly-owned subsidiary of the Group, has been declared for marketing and accepted by China's National Drug Administration (“State Drug Administration”). The specific indications for this report are: It is suitable for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) positive for anaplastic lymphoma kinase (ALK). Dacitinib tablets submitted a marketing application for Xuanzhu Biotech and
Citibank: Reiterates BYD Electronics' (00285.HK) “Buy” Rating Target Price Reduced to HK$39
Citi released a research report stating that it reaffirmed the “buy” rating of BYD Electronics (00285.HK) and lowered the target price from HK$47 to HK$39. Recent catalysts include the launch of the new iPad Pro and the replenishment of iPhones starting in the third quarter.
Hong Kong biotechnology stocks continued to rise, with Pharmaceuticals up more than 5%, Pharmaceutical and Junshi Biotech up more than 4%, Goli Pharmaceuticals up more than 3%, and Tiger Pharmaceuticals up more than 2%.
Hong Kong biotechnology stocks continued to rise, with Pharmaceuticals up more than 5%, Pharmaceutical and Junshi Biotech up more than 4%, Goli Pharmaceuticals up more than 3%, and Tiger Pharmaceuticals up more than 2%.
The Hang Seng Index rose more than 2%, the Hang Seng Technology Index rose 3.7%, Hong Kong biotech stocks rose higher, Cansino Biotech rose more than 10%, and Rongchang Biotech rose more than 6%.
The Hang Seng Index rose more than 2%, the Hang Seng Technology Index rose 3.7%, Hong Kong biotech stocks rose higher, Cansino Biotech rose more than 10%, and Rongchang Biotech rose more than 6%.
The Hang Seng Index rose more than 1%. Among the constituent stocks, Meituan rose more than 5%, Country Garden Services rose more than 4%, and JD Health, BYD shares, and Tencent Holdings rose more than 2%.
The Hang Seng Index rose more than 1%. Among the constituent stocks, Meituan rose more than 5%, Country Garden Services rose more than 4%, and JD Health, BYD shares, and Tencent Holdings rose more than 2%.
BYD Electronic's Q1 Profit Jumps 33%
BYD Electronic's (HKG:0285) attributable profit rose 33% to 610.4 million yuan, or 0.27 yuan per share, in the first quarter, from 458.9 million yuan, or 0.20 yuan per share, in the year-ago period, a
Tong Ren Tang Registers Danggui Buxue Granules in Hong Kong
Beijing Tong Ren Tang Group (SHA:600085) received the certificate of registration from Hong Kong's Chinese Medicine Council for Danggui Buxue granules, according to the company's filing on the Shangha
Beijing Tong Ren Tang Gets Nod to Sell Fever Drug in Hong Kong
Beijing Tong Ren Tang Chinese Medicine (HKG:3613), a unit of Tong Ren Tang Technologies (HKG:1666), has obtained approval to sell its drug Danggui Buxue Keli in Hong Kong, a Tuesday filing by the latt
Sinopharm Holdings (01099.HK): Main business maintains growth trend, transformation and innovation continue to advance
Revenue for the first quarter of 2024 was in line with our expectations, and net profit was slightly lower than our expectations. The company announced the results for the first quarter of 2024: revenue of RMB 147.27 billion, an increase of 1.2% over the previous year, and net profit attributable to the parent company RMB
Fosun Pharma's Q1 Profit Slumps 38%
Shanghai Fosun Pharmaceutical (Group) (HKG:2196, SHA:600196) posted a net profit attributable to owners of 609.7 million yuan in the first quarter of 2024, slumping 38.2% from 987 million yuan a year